Scarica l'app Stockscreener
5.49
0.92%
0.05
Dopo l'orario di chiusura:
5.50
0.010
+0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.44
Aprire:
$5.49
Volume 24 ore:
577.30K
Relative Volume:
0.47
Capitalizzazione di mercato:
$312.90M
Reddito:
$5.82M
Utile/perdita netta:
$71.18M
Rapporto P/E:
5.5054
EPS:
0.9972
Flusso di cassa netto:
$-84.30M
1 W Prestazione:
+7.23%
1M Prestazione:
+1.86%
6M Prestazione:
+6.60%
1 anno Prestazione:
-14.49%
Intervallo 1D:
$5.41
$5.5471
Intervallo di 1 settimana:
$5.11
$5.63
Portata 52W:
$4.00
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Nome
Abeona Therapeutics Inc
Settore
Industria
Telefono
646-813-4701
Indirizzo
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.49 | 310.05M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-03-05 | Iniziato | Oppenheimer | Outperform |
| 2024-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-30 | Iniziato | Stifel | Buy |
| 2020-11-11 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-02-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-10 | Ripresa | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Downgrade | Maxim Group | Buy → Hold |
| 2019-08-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Downgrade | Mizuho | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2018-10-12 | Iniziato | Mizuho | Buy |
| 2018-06-05 | Iniziato | Seaport Global Securities | Buy |
| 2017-11-08 | Iniziato | SunTrust | Buy |
| 2017-10-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Iniziato | Citigroup | Buy |
| 2017-10-05 | Reiterato | Maxim Group | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-18 | Reiterato | Maxim Group | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-01-06 | Iniziato | Jefferies | Buy |
| 2016-09-29 | Reiterato | Maxim Group | Buy |
Mostra tutto
Abeona Therapeutics Inc Borsa (ABEO) Ultime notizie
Abeona Therapeutics (ABEO) director reports bona fide 500-share gift - Stock Titan
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - The Manila Times
Abeona plans Jefferies fireside chat, Goldman investor meetings - Stock Titan
Lightning eMotors Inc. (ZEV) - Minichart
Insider Sell: Mark Alvino Sells 6,500 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics director Mark Alvino sells $35,462 in stock By Investing.com - Investing.com South Africa
Abeona Therapeutics director Mark Alvino sells $35,462 in stock - Investing.com UK
Abeona Therapeutics (ABEO) director sells 6,500 shares in open-market trade - Stock Titan
[144] ABEONA THERAPEUTICS INC. SEC Filing - Stock Titan
May 2026's Top Insider-Owned Growth Companies - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Abeona Therapeutics (NASDAQ: ABEO) Reports $8.7 Million in Q1 Revenue as ZEVASKYN Adoption Accelerates - foreignpolicyjournal.com
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum - TipRanks
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
(ABEO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ABEO: Three Patients Treated in 1Q26 with Two Additional QTCs Activated - Zacks Small Cap Research
Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips - Investing.com
Abeona Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Abeona Therapeutics Q1 2026 earnings preview - MSN
Abeona (ABEO) director 10b5-1 open-market sale of 26,143 shares - Stock Titan
Nantahala (ABEO) reports 5.78M-share 9.99% stake; managers Harkey, Mack listed - Stock Titan
Nantahala Capital reports 3.33M shares in Abeona (ABEO) as of March 31, 2026 - Stock Titan
ABEO (Nasdaq) Form 144: Insider proposes sale; restricted awards listed - Stock Titan
Jefferies Remains a Buy on Abeona Therapeutics (ABEO) - The Globe and Mail
Abeona Therapeutics (ABEO) Gets a Buy from Oppenheimer - The Globe and Mail
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript - Sahm
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network - Sahm
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics Inc (ABEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - GuruFocus
Abeona Therapeutics Signals Strong Early ZEVASKYN Launch - TipRanks
Abeona Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Abeona (ABEO) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings Call Summary | Abeona Therapeutics(ABEO.US) Q1 2026 Earnings Conference - Moomoo
Abeona Therapeutics Q1 2026: Loss Narrows to $0.30/Share - AlphaStreet
Abeona Therapeutics (ABEO) Reports Strong Q1 Earnings with Reven - GuruFocus
Abeona Therapeutics Q1 Earnings Call Highlights - sharewise.com
Abeona Therapeutics Inc. Q1 2026 Financial Report: Key Highlights, Risk Factors, and ZEVASKYN Commercialization Update - Minichart
Abeona Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Abeona Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Abeona Therapeutics Reports Q1 2026 Results: Strong ZEVASKYN Adoption, Pipeline Focus on PSMA T-Cell Therapy, and $168M Cash Position - Minichart
Earnings call transcript: Abeona Therapeutics Q1 2026 beats expectations with strong revenue - Investing.com
Earnings call transcript: Abeona Therapeutics Q1 2026 beats expectations with strong revenue By Investing.com - Investing.com South Africa
Abeona Therapeutics (ABEO) Reports Strong Q1 Revenue Growth - GuruFocus
ABEO: Q1 revenue surged on ZEVASKYN uptake; profitability targeted by June; pipeline expands to oncology - TradingView
Abeona Therapeutics Deprioritizes In-House Ophthalmology Programs >ABEO - Moomoo
Is Abeona Therapeutics (ABEO) Appropriately Valued After a Q1 20 - GuruFocus
Abeona Therapeutics Inc Azioni (ABEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):